Should You Buy Johnson & Johnson For Its COVID Vaccine?
So far, some coronavirus vaccine stocks have offered investors enormous gains in a short period of time. For example, Moderna (NASDAQ: MRNA) stock climbed more than 400% last year as investors bet on its investigational vaccine. At the same time, Pfizer (NYSE: PFE) fell less than 1% last year -- even though the company led the vaccine race along with Moderna. In fact, Pfizer's vaccine eventually became the first to win Emergency Use Authorization (EUA). Moderna earned its EUA about a week later.
Investing in either of those companies for their COVID-19 vaccines brought vastly different results. Now, let's look ahead at the next company to possibly enter the market. Johnson & Johnson's (NYSE: JNJ) candidate is currently in phase 3 trials, and interim data is expected later this month. If all is positive, Johnson & Johnson might be the third to cross the vaccine race finish line. Should investors consider buying shares of the pharmaceutical giant for that reason? Let's take a closer look.
Image source: Getty Images.
Source Fool.com
